2027 Pharma Marketing Trends: 10 Predictions for Pharma Content & HCP Engagement

Pharma is approaching 2027 from a strange, paradoxical place. Thanks to AI, it has never been easier to create pharma content, and it has never been harder to get it used.

Pharma has spent a decade adding channels, collecting data, optimizing CRM, and moving towards more sophisticated omnichannel technology. Now AI can draft, adapt, translate, and repurpose content faster than most of us expected a few years ago.

Producing content no longer seems to be the hard part of pharma marketing. Making it relevant, useful and worth a healthcare professional’s (HCP’s) time is.

At the same time, HCP access is getting harder. Veeva Pulse found that U.S. HCP access fell from 60% in 2022 to 45% in 2024. So we can create more content, faster, for doctors we have fewer chances to reach.

Something has to give. We started thinking about where it gives first, and that led us to ten predictions for pharma marketing in 2027.

1. Content utilization becomes the KPI that finally matters

Pharma has become very good at measuring what it produces: assets created, approval times, local adaptations, and campaign deliverables.

But nearly 80% of approved content is rarely or never used.

That number should make us uncomfortable. Unused content still went through briefing, creation, review, approval, and often localization. All of that work and budget went into content that ultimately sat unused.

For years, pharma has focused on making content production faster and more efficient. In 2027, more teams will start asking a different question: was this content actually worth producing?

2. AI moves the value from content production to content judgment

AI is making pharma content much easier to produce, with an awkward side effect: it’s also making it easier to produce more of it.

Even before generative AI really took hold, content volumes were already climbing. Veeva reported that U.S. biopharma commercial content production rose 29% in 2023, with companies collectively adding 25,000 new pieces of content per week.

AI can make that machine run even faster. If somebody says, “we need a new asset” and nobody asks why, the wrong asset just gets produced sooner.

This makes judgment much more important. What are HCPs asking? What does the field actually use? What can already be reused? What needs to go into the piece, and what can be left out? And sometimes, do we need to create anything new at all?

Those questions will become just as important as how quickly the content can be produced.

3. HCP interests and questions start leading the next content brief

Most pharma content plans start with what the brand wants to say: key messages, the scientific narrative, strategic priorities, and campaign plans. All of that still matters.

But something else is going to have a much bigger say in the next brief: what are HCPs actually interested in, asking about, and trying to understand?

Pharma already hears those signals every day. Reps, medical science liaisons (MSLs) and Medical Information each hear a different set. Veeva’s 2026 Agentic Commercial Trends Report found that Agentic Call Reports uncovered barriers to treatment adoption in 65% of field interactions.

AI is making it easier to capture and analyze those signals, which means they can become a much more useful input into content planning.

For years, we’ve started with “What do we need to tell HCPs?” In 2027, “What are HCPs telling us they need?” will have a much bigger influence on what gets created next.

4. “Modular content” finally reaches the HCP

Pharma has done serious work on modular content. Claims are structured, references are linked, and components can be approved and reused. But most of that modularity still happens behind the scenes. Before it reaches the HCP, those modules are often assembled back into a presentation, PDF or interactive visual aid (iVA).

We think that starts to change in 2027. Individual modules will increasingly make their way to the HCP and make sense on their own, with the references and wider scientific story still there when someone wants to go deeper.

A doctor doesn’t always need the whole scientific story to answer one question. Sometimes they need one part of it. The opportunity now is to make modular content work for the HCP too, rather than stopping at a more efficient content production process.

This is where medical micro-content comes in: focused, referenced content that makes individual pieces of science useful to HCPs without requiring them to work through the entire presentation.

5. MLR starts before the asset exists

For years, MLR has mostly happened after the asset was created: the copy is written, the references are added, the iVA is designed, and then Medical, Legal, and Regulatory review the finished thing.

Anyone who has worked through 34 comments in round one, only to get 11 new ones in round two, knows how that goes.

More of the review thinking will start moving earlier. Claims, evidence, references, audience, and intended use can be considered while the content is being created, rather than pieced together when it’s ready for submission.

AI makes this more urgent. If content production gets dramatically faster while review stays the same, MLR simply becomes the queue where all that extra content ends up.

The connections made during review matter after approval too. If a claim is connected to its evidence from the beginning, that relationship can stay intact when the content is reused, localized, or updated.

Faster MLR shouldn't mean less MLR. It should mean building content in a system that has MLR in mind from the start.

6. Human-verified becomes the new premium in pharma content

Merriam-Webster's word of the year for 2025 was “slop”: low-quality digital content produced in quantity by AI.

Pharma isn't immune. AI is making it easier for everyone to publish summaries, chatbot answers, articles, and scientific-looking content where the origin and reliability aren't always clear.

HCPs are concerned about that. In Doximity's 2026 State of AI in Medicine report, 71% of physicians surveyed named the accuracy and reliability of AI-generated outputs as a concern. It was the most-cited concern across all age groups and all 15 specialties studied.

That puts pharma in an interesting position. We already have people accountable for reviewing the science, checking claims, and verifying references. We’ve traditionally talked about that process mainly in terms of compliance and how long it takes. In an internet filling up with AI-generated information, the fact that somebody has actually checked the science may become more valuable.

7. Marketing materials start to look like Medical Affairs made them

Ask brand teams what they’re hearing lately and the request is surprisingly consistent: make it less flashy.

That usually means pulling back on lifestyle imagery and animation, while giving more space to data, references, and the science itself. The tone starts to feel closer to a colleague walking through a study than a brand-selling one.

There’s evidence behind that shift. Graphite Digital’s research with HCPs in the U.S., UK, and France found that 80% of the HCPs they spoke to cited a lack of trust in pharma-provided digital content and channels as a concern, with promotional tone and the objectivity of data among the issues raised.

Commercial and Medical will, of course, remain separate. But HCP marketing will become more scientific, evidence-first and restrained in how the brand shows up.

The brand doesn’t disappear. It just stops shouting.

8. Omnichannel becomes less about channels and more about context

Pharma has spent years orchestrating channels: rep visits, email, websites, webinars, congresses, and portals. But even a perfectly orchestrated journey can fail if the content at the end of it doesn’t fit the moment.

Doctors open emails between patients, look things up on their phones during a visit, and scan a rep’s QR code hours after a meeting. The same HCP can need very different things depending on where they are, what they’re doing, and how much time they have.

We’ve spent a lot of time thinking about which channel comes next. In 2027, more attention will go to what happens at the end of that channel. What does the HCP need at that moment? How much information is useful? What format makes sense? And if they want to go deeper, can they?

The channel can get the HCP there. The content still has to work when they arrive.

9. Congress success will be measured by what happens next

Pharma puts enormous effort into congresses, but a congress lasts a few days and the science discussed there needs to be useful for much longer.

IQVIA reports that 90% of HCPs say access to information beyond the event helps them apply new medical approaches faster.

Yet congress planning still tends to focus heavily on what happens on site: booth traffic, badge scans, meetings and symposia. And most of us have seen where the printed leave-behinds end up.

Congress teams will start paying much more attention to what happens after the HCP walks away. Did they come back to the science? Could they find the specific information they were interested in? Was it still useful when a question came up two weeks later?

A QR code can take an HCP back to the specific science they stopped to discuss, with the wider story available when they want more. That gives congress engagement a life beyond the few days everyone happens to be in the same convention center.

10. Long-form content stops being the default

For years, short-form pharma content has usually been created from something bigger: a snippet from the “real” asset, a webinar teaser, a social post pointing somewhere else. The long-form asset came first, and everything shorter was derived from it.

HCPs are already behaving differently. According to the American Medical Association’s 2026 Physician Survey on Augmented Intelligence (AMA), nearly 40% of physicians use AI to summarize medical research and standards of care, up 26 percentage points since 2024.

Doctors still want the science. They’re finding faster ways into it.

Pharma will start designing more content around that behavior. Short-form science can be created as useful content in its own right rather than starting with a long asset and cutting it down afterwards. Medical micro-content takes that thinking further. Instead of cutting a long asset into smaller pieces afterwards, teams can create focused, referenced content around the specific questions HCPs need answered, while keeping the supporting evidence accessible.

Long-form content still has an important role. Sometimes the HCP needs the full study, deck, or scientific story. Sometimes they need one answer in the few minutes they have. Designing for both means thinking about that moment from the beginning and keeping the evidence, references and route to the wider story accessible.

The science doesn’t get smaller. The default way into it does.

One shift behind all ten

At Qoolo, we believe medical micro-content will play a much bigger role in pharma marketing in 2027. Focused, referenced content built around what HCPs actually need. Because how scientific information is structured and delivered matters just as much as how quickly it's created.

Behind these predictions is a fairly simple shift. Pharma is getting very good at producing content. Now we need to get much better at getting value from it.

That changes the questions we ask about content: what should we create, what will actually get used, what can be reused, and does it work for the HCP when it finally reaches them?

2027 will be fun.